Unveiling innovative anti-influenza agents through modern medicinal chemistry approaches (2019-2023 updates).

Future Medicinal ChemistryAhead of Print EditorialUnveiling innovative anti-influenza agents through modern medicinal chemistry approaches (2019–2023 updates)Chuanfeng Liu‡, Lide Hu‡, Huinan Jia, Jiwei Zhang, Guanyu Dong, Edeildo Ferreira da Silva-Júnior, Xinyong Liu & Peng ZhanChuanfeng Liu‡Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan, Shandong, 250012, P.R. ChinaSuzhou Research Institute of Shandong University, Room 607, Building B of NUSP, No. 388 Ruoshui Road, SIP, Suzhou, Jiangsu, 215123, P.R. China‡These authors contributed equallySearch for more papers by this author, Lide Hu‡Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan, Shandong, 250012, P.R. China‡These authors contributed equallySearch for more papers by this author, Huinan JiaDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan, Shandong, 250012, P.R. ChinaSearch for more papers by this author, Jiwei ZhangDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan, Shandong, 250012, P.R. ChinaSearch for more papers by this author, Guanyu DongDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan, Shandong, 250012, P.R. ChinaSearch for more papers by this author, Edeildo Ferreira da Silva-JúniorBiological & Molecular Chemistry Research Group, Institute of Chemistry & Biotechnology, Federal University of Alagoas, Lourival Melo Mota Avenue, AC. Simoesõ Campus, Alagoas, Maceió, 57072-970, BrazilSearch for more papers by this author, Xinyong Liu**Author for correspondence: E-mail Address: xinyongl@sdu.edu.cnDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan, Shandong, 250012, P.R. ChinaSearch for more papers by this author & Peng Zhan *Author for correspondence: E-mail Address: zhanpeng1982@sdu.edu.cnhttps://orcid.org/0009-0003-4356-4594Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan, Shandong, 250012, P.R. ChinaSearch for more papers by this authorPublished Online:6 Nov 2023https://doi.org/10.4155/fmc-2023-0258AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: drug design strategiesinfluenza virusmedicinal chemistryReferences1. Yamayoshi S, Kawaoka Y. Current and future influenza vaccines. Nat. Med. 25(2), 212–220 (2019).Crossref, Medline, CAS, Google Scholar2. Zhang Q, Liang T, Nandakumar KS et al. Emerging and state of the art hemagglutinin-targeted influenza virus inhibitors. Expert Opin. Pharmacother. 22(6), 715–728 (2021).Crossref, Medline, CAS, Google Scholar3. Kiso M, Yamayoshi S, Kawaoka Y. Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors. J. Antimicrob. Chemother. 78(7), 1649–1657 (2023).Crossref, Medline, Google Scholar4. Liu C, Hu L, Dong G et al. Emerging drug design strategies in anti-influenza drug discovery. Acta Pharm. Sin. B. doi:10.1016/j.apsb.2023.08.010 (2023) (Epub ahead of print).Google Scholar5. Jia R, Zhang J, Ju H et al. Discovery of novel anti-influenza agents via contemporary medicinal chemistry strategies (2014–2018 update). Future Med. Chem. 11(5), 375–378 (2019).Link, CAS, Google Scholar6. Zhou Y, Xu SJ, López-Carrobles N et al. Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality. Acta Materia. Medica. 2(3), 285–298 (2023).Crossref, Google Scholar7. Xiao M, Zhao J, Wang Q et al. Recent advances of degradation technologies based on PROTAC mechanism. Biomolecules 12(9), 1257 (2022).Crossref, Medline, CAS, Google Scholar8. Gao H, Sun X, Rao Y. PROTAC technology: opportunities and challenges. ACS Med. Chem. Lett. 11(3), 237–240 (2020).Crossref, Medline, CAS, Google Scholar9. Xu ZC, Liu XJ, Ma XY et al. Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus. Cell Insight 1(3), 100030 (2022).Crossref, Medline, Google Scholar10. Li H, Wang S, Ma W et al. Discovery of pentacyclic triterpenoid PROTACs as a class of effective hemagglutinin protein degraders. J. Med. Chem. 65(10), 7154–7169 (2022).Crossref, Medline, CAS, Google Scholar11. Zhao J, Wang J, Pang X et al. An anti-influenza A virus microbial metabolite acts by degrading viral endonuclease PA. Nat. Commun. 13(1), 2079 (2022).Crossref, Medline, CAS, Google Scholar12. Charles WZ, Faries CR, Street YT et al. Antibody-recruitment as a therapeutic strategy: a brief history and recent advances. Chembiochem 23(16), e202200092 (2022).Crossref, Medline, CAS, Google Scholar13. Liu X, Zhang B, Wang Y et al. A universal dual mechanism immunotherapy for the treatment of influenza virus infections. Nat. Commun. 11(1), 5597 (2020).Crossref, Medline, CAS, Google Scholar14. Liu KC, Fang JM, Jan JT et al. Enhanced anti-influenza agents conjugated with anti-inflammatory activity. J. Med. Chem. 55(19), 8493–8501 (2012).Crossref, Medline, CAS, Google Scholar15. Lv X, Wang P, Li C et al. Zanamivir–cholesterol conjugate: a long-acting neuraminidase inhibitor with potent efficacy against drug-resistant influenza viruses. J. Med. Chem. 64(23), 17403–17412 (2021).Crossref, Medline, CAS, Google Scholar16. Liu X, Luo W, Zhang B et al. Design of neuraminidase-targeted imaging and therapeutic agents for the diagnosis and treatment of influenza virus infections. Bioconjug. Chem. 32(8), 1548–1553 (2021).Crossref, Medline, CAS, Google Scholar17. Kinowaki Y, Taguchi T, Onishi I et al. Overview of ferroptosis and synthetic lethality strategies. Int. J. Mol. Sci. 22(17), 9271 (2021).Crossref, Medline, CAS, Google Scholar18. Domostegui A, Nieto-Barrado L, Perez-Lopez C et al. Chasing molecular glue degraders: screening approaches. Chem. Soc. Rev. 51(13), 5498–5517 (2022).Crossref, Medline, CAS, Google Scholar19. Russo G, Reche P, Pennisi M et al. The combination of artificial intelligence and systems biology for intelligent vaccine design. Expert Opin. Drug Discov. 15(11), 1267–1281 (2020).Crossref, Medline, CAS, Google Scholar20. Du J, Guo J, Kang D et al. New techniques and strategies in drug discovery. Chin. Chem. Lett. 31, 1695–1708 (2020).Crossref, CAS, Google ScholarFiguresReferencesRelatedDetails Ahead of Print STAY CONNECTED Metrics Downloaded 0 times History Received 1 September 2023 Accepted 19 September 2023 Published online 6 November 2023 Information© 2023 Newlands PressKeywordsdrug design strategiesinfluenza virusmedicinal chemistryAuthor contributionsThe writing of the first draft was initiated by C Liu, L Hu and H Jia. J Zhang, G Dong, EF da Silva-Júnior, X Liu and P Zhan edited the manuscript. P Zhan reviewed and approved the final manuscript.Financial disclosureThe authors have received financial support from the National Natural Science Foundation of China (NSFC nos. 82173677, 82211530493), Science Foundation for Outstanding Young Scholars of Shandong Province (ZR2020JQ31), Natural Science Foundation of Jiangsu Province (SBK2023041680) and China Postdoctoral Science Foundation (2022M711938). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.Competing interests disclosureThe authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.Writing disclosureNo writing assistance was utilized in the production of this manuscript.PDF download